GENMAB A/SGMABEarnings & Financial Report
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
GMAB Q2 2025 Key Financial Metrics
Revenue
$925.0M
Gross Profit
$868.0M
Operating Profit
$360.0M
Net Profit
$336.0M
Gross Margin
93.8%
Operating Margin
38.9%
Net Margin
36.3%
YoY Growth
18.7%
EPS
$5.42
Financial Flow
GENMAB A/S Q2 2025 Financial Summary
GENMAB A/S reported revenue of $925.0M for Q2 2025, with a net profit of $336.0M (36.3% margin). Cost of goods sold was $57.0M, operating expenses totaled $508.0M.
Key Financial Metrics
| Total Revenue | $925.0M |
|---|---|
| Net Profit | $336.0M |
| Gross Margin | 93.8% |
| Operating Margin | 38.9% |
| Report Period | Q2 2025 |
Income Statement
| Q2 2024 | Q2 2025 | |
|---|---|---|
| Revenue | $779.0M | $925.0M |
| YoY Growth | N/A | 18.7% |
Balance Sheet
| Q2 2024 | Q2 2025 | |
|---|---|---|
| Assets | N/A | $6.46B |
| Liabilities | N/A | $1.16B |
| Equity | $4.45B | $5.30B |
Cash Flow
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M
BIO
BIO-RAD LABORATORIES, INC.
Revenue
$693.2M
Net Profit
$720.0M